Horvātija - horvātu - HALMED (Agencija za lijekove i medicinske proizvode)

accord healthcare polska sp. z o.o., ul. tasmowa 7, mazowieckie, varšava, poljska - темсиролимус - koncentrat i otapalo za otopinu za infuziju - 30 mg - urbroj: jedna bočica koncentrata za otopinu za infuziju sadrži 30 mg temsirolimusa

Eiropas Savienība - horvātu - EMA (European Medicines Agency)

jazz pharmaceuticals ireland limited - crisantaspase - prekursorska stanica limfoblastične leukemije-limfom - antineoplastična sredstva - enrylaze is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukaemia (all) and lymphoblastic lymphoma (lbl) in adult and paediatric patients (1 month and older) who developed hypersensitivity or silent inactivation to e. coli-derived asparaginase.

Horvātija - horvātu - HALMED (Agencija za lijekove i medicinske proizvode)

sandoz d.o.o., maksimirska 120, zagreb - darunavirum - filmom obložena tableta - 600 mg - urbroj: svaka filmom obložena tableta sadrži 600 mg darunavira

Horvātija - horvātu - HALMED (Agencija za lijekove i medicinske proizvode)

sandoz d.o.o., maksimirska 120, zagreb - darunavirum - filmom obložena tableta - 75 mg - urbroj: svaka filmom obložena tableta sadrži 75 mg darunavira

Horvātija - horvātu - HALMED (Agencija za lijekove i medicinske proizvode)

cipla europe nv, de keyserlei 58-60, box-19, antwerpen, belgija - valganciklovirklorid - filmom obložena tableta - 450 mg - urbroj: svaka filmom obložena tableta sadrži valganciklovirklorid, što odgovara 450 mg valganciklovira

Horvātija - horvātu - HALMED (Agencija za lijekove i medicinske proizvode)

stada d.o.o., hercegovačka 14, zagreb, hrvatska - valganciklovirklorid - filmom obložena tableta - 450 mg - urbroj: jedna tableta sadrži 496,3 mg valganciklovirklorida što odgovara 450 mg valganciklovira (kao slobodna baza)

Melnkalne - horvātu - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

"evropa lek" doo podgorica - vinorelbin - koncentrat za rastvor za infuziju - 10mg/ml

Melnkalne - horvātu - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

"evropa lek" doo podgorica - vinorelbin - koncentrat za rastvor za infuziju - 10mg/ml

Eiropas Savienība - horvātu - EMA (European Medicines Agency)

baxter holding b.v. - doksorubicin hidroklorid - sarcoma, kaposi; multiple myeloma; ovarian neoplasms; breast neoplasms - antineoplastična sredstva - caelyx пегилированный liposomal glasi:kao monoterapija u bolesnika s metastaze raka dojke, gdje postoji povećan rizik od srčanih bolesti., za liječenje popularnog raka jajnika kod žena koje nisu uspjeli u prvoj liniji na bazi platine kemoterapije terapije, u kombinaciji s бортезомибом za liječenje progresivne multiple myeloma kod bolesnika koji su primili barem jedan tečaj terapija i koji su već prošli ili neprikladan za transplantacije koštane srži;za liječenje povezanih sa aids-om kaposijev sarkom (sk) u bolesnika s niskim cd4 (.

Eiropas Savienība - horvātu - EMA (European Medicines Agency)

sandoz gmbh - rituksimab - lymphoma, non-hodgkin; arthritis, rheumatoid; microscopic polyangiitis; wegener granulomatosis - antineoplastična sredstva - riximyo is indicated in adults for the following indications:non-hodgkin’s lymphoma (nhl)riximyo is indicated for the treatment of previously untreated adult patients with stage iii-iv follicular lymphoma in combination with chemotherapy. riximyo maintenance therapy is indicated for the treatment of adult follicular lymphoma patients responding to induction therapy. riximyo monotherapy is indicated for treatment of adult patients with stage iii-iv follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy. riximyo is indicated for the treatment of adult patients with cd20 positive diffuse large b cell non-hodgkin’s lymphoma in combination with chop (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy. riximyo in combination with chemotherapy is indicated for the treatment of paediatric patients (aged ≥ 6 months to < 18 years old) with previously untreated advanced stage cd20 positive diffuse large b-cell lymphoma (dlbcl), burkitt lymphoma (bl)/burkitt leukaemia (mature b-cell acute leukaemia) (bal) or burkitt-like lymphoma (bll). chronic lymphocytic leukaemia (cll)riximyo in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia. postoje samo ograničeni podaci o učinkovitosti i sigurnosti bolesnika prethodno liječenih monoklonsko antitijelo, uključujući rituksimab ili bolesne, vatrostalne standardnim tretmanima na prethodnu rituksimab + kemoterapija. cm. odjeljak 5. 1 za daljnje informacije. rheumatoid arthritisriximyo in combination with methotrexate is indicated for the treatment of adult patients with severe active rheumatoid arthritis who have had an inadequate response or intolerance to other disease-modifying anti-rheumatic drugs (dmard) including one or more tumour necrosis factor (tnf) inhibitor therapies. rituksimab je pokazala da smanjuje brzinu progresije oštećenja zglobova kao što se mjeri x-ray i poboljšati fizičku funkciju, prilikom raspoređivanja u kombinaciji s metotreksatom. granulomatosis with polyangiitis and microscopic polyangiitisriximyo, in combination with glucocorticoids, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (wegener’s) (gpa) and microscopic polyangiitis (mpa). riximyo, in combination with glucocorticoids, is indicated for the induction of remission in paediatric patients (aged ≥ 2 to < 18 years old) with severe, active gpa (wegener’s) and mpa. pemphigus vulgarisriximyo is indicated for the treatment of patients with moderate to severe pemphigus vulgaris (pv).